中信建投证券股份有限公司 关于北京天智航医疗科技股份有限公司 首次公开发行股票并在科创板上市之保荐总结报告书 一、保荐机构及保荐代表人承诺 1、保荐总结报告书和证明文件及其相关资料的内容不存在虚假记载、误导 性陈述或重大遗漏，保荐机构及保荐代表人对其真实性、准确性、完整性承担法 律责任。 2、本机构及本人自愿接受中国证监会对保荐总结报告书相关事项进行的任 何质询和调查。 3、本机构及本人自愿接受中国证监会按照《证券发行上市保荐业务管理办 法》的有关规定采取的监管措施。 | 保荐机构名称 | 中信建投证券股份有限公司 | | --- | --- | | 注册地址 | 北京市朝阳区安立路 66 号 4 号楼 | | 主要办公地址 | 北京市朝阳区景辉街 16 号院 1 号楼泰康集团大厦 10 层 | | 法定代表人 | 王常青 | | 本项目保荐代表人 | 孙栋、陆丹君 | | 项目联系人 | 孙栋 | | 联系电话 | 010-56051503 | | 是否更换保荐人或其他情况 | 2022 年 4 月 13 日，汪家胜先生因工作变动，不再继续担 任天智航持续督导保荐代表人，中信建投委派保荐代表人 | | | ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥28,944,718.96, representing a decrease of 26.73% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥10,063,239.85, a decline of 216.49% year-over-year[5]. - The net cash flow from operating activities was -¥49,952,267.09, indicating a significant cash outflow[5]. - In Q1 2024, the company reported a net loss of CNY 10,063,239.85, compared to a net profit of CNY 3,728,197.47 in Q1 2023, representing a significant decline[21]. - The company’s total comprehensive income for Q1 2024 was CNY -10,049,093.81, down from CNY 3,624,921.95 in Q1 2023[22]. - The basic and diluted earnings per share for Q1 2024 were both CNY -0.02, compared to CNY 0.02 in Q1 2023[22]. Research and Development - Research and development expenses totaled ¥27,627,966.18, accounting for 95.45% of operating revenue, an increase of 29.51 percentage points from the previous year[6]. - The company’s development expenses increased to RMB 8,687,737.51 in Q1 2024, up from RMB 6,950,961.94 in Q1 2023, representing an increase of approximately 25%[17]. - Research and development expenses were CNY 25,891,190.61 in Q1 2024, slightly down from CNY 26,050,050.56 in Q1 2023[21]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,583,557,867.24, down 2.22% from the end of the previous year[6]. - The total assets as of March 31, 2024, were RMB 1,583,557,867.24, a decline from RMB 1,619,474,854.92 at the end of 2023[18]. - The total liabilities decreased to RMB 349,724,155.42 from RMB 381,951,829.60 at the end of 2023, indicating a reduction of approximately 8.4%[18]. - The company's long-term equity investments decreased to RMB 78,389,227.86 from RMB 93,289,065.43, reflecting a decline of about 15.9%[16]. - The company reported a net loss of RMB 477,279,887.14 in retained earnings as of March 31, 2024, compared to a loss of RMB 467,216,647.29 at the end of 2023[18]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 17,314[11]. - The top shareholder, Zhang Songgen, holds 75,664,000 shares, representing 16.84% of the total shares[11]. Cash Flow and Expenses - The company's cash and cash equivalents decreased to RMB 279,022,807.26 as of March 31, 2024, down from RMB 310,857,521.05 at the end of 2023[16]. - The company's operating cash flow for Q1 2024 was negative at CNY -49,952,267.09, an improvement from CNY -90,397,892.83 in Q1 2023[24]. - Cash and cash equivalents at the end of Q1 2024 were CNY 278,815,053.04, down from CNY 490,658,668.02 at the end of Q1 2023[25]. - The company incurred total sales expenses of CNY 22,132,576.97 in Q1 2024, a decrease from CNY 30,797,046.70 in Q1 2023, reflecting a reduction of approximately 28.3%[21]. Operational Metrics - The number of surgeries performed using the Tianji orthopedic surgical robot exceeded 8,000 in Q1 2024, marking an increase of over 80% year-on-year[13]. - As of the report date, the cumulative number of surgeries conducted with the Tianji orthopedic surgical robot surpassed 70,000[13]. - The total operating costs for Q1 2024 were RMB 79,862,623.61, down from RMB 94,531,368.13 in the same period last year, representing a reduction of about 15.6%[20]. - The company experienced a significant increase in the cash received from sales and services compared to the previous year, contributing to a reduction in operating expenses[9]. Investment Income - The company reported investment income of CNY 33,591,207.78 in Q1 2024, a decrease from CNY 48,548,114.13 in Q1 2023, indicating a decline of approximately 30.8%[21]. - Investment activities generated a net cash inflow of CNY 12,551,675.34 in Q1 2024, compared to CNY 13,417,405.60 in Q1 2023, showing a slight decrease[24].

北京天智航医疗科技股份有限公司 董事会对在任独立董事独立性情况评估的专项意见 根据《上市公司独立董事管理办法》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》的有关规定及北京天智航医疗科技股份有限公司 （以下简称"公司"）《独立董事工作制度》的相关要求，公司董事会就在任独立 董事的独立性情况进行评估并出具专项意见如下： 经核查在任独立董事李志勇、张瑞君、徐扬的任职经历以及签署的相关自查 文件， 上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股 东公司担任任何职务，与公司以及主要股东、实际控制人之间不存在利害关系或 其他可能妨碍其进行独立客观判断的关系，符合《上市公司独立董事管理办法》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》中关于独 立董事独立性的相关要求。 北京天智航医疗科技股份有限公司董事会 2024 年 4 月 25 日 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京天智航医疗科技股份有限公司（以下简称"公司"）于 2024 年 4 月 25 日召开第六届董事会第十次会议、第四届监事会第二十一次会议，分别逐项审议 通过了《关于提请股东大会授权董事会办理以简易程序向特定对象发行股票相关 事宜的议案》。本议案尚需提交公司股东大会审议通过。具体情况如下： 根据《上市公司证券发行注册管理办法》《公司章程》等相关规定，公司董 事会提请股东大会授权董事会决定公司向特定对象发行融资总额不超过人民币 3 亿元且不超过最近一年末净资产 20%的股票，授权期限自公司 2023 年年度股 东大会审议通过之日起至公司 2024 年年度股东大会召开之日止。 本次授权事宜包括但不限于以下内容： 1. 确认公司是否符合以简易程序向特定对象发行股票条件 证券代码：688277 证券简称：天智航 公告编号：2024-020 北京天智航医疗科技股份有限公司 关于提请股东大会授权董事会以简易程序向特定对象 发行股票的公告 授权董事会根据《中华人民共和国公司法》《中华人民共 ...

重要内容提示： 1、北京天智航医疗科技股份有限公司（以下简称"公司"）2023年度拟不进 行利润分配、不进行资本公积金转增股本和其他形式的分配。 2、本次利润分配方案已经公司第六届董事会第十次会议和第四届监事会第 二十一次会议审议通过，尚需提交公司2023年年度股东大会审议。 一、2023年度利润分配方案 证券代码：688277 证券简称：天智航 公告编号：2024-017 北京天智航医疗科技股份有限公司 关于公司 2023 年度利润分配方案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司于2024年4月25日召开第六届董事会第十次会议，审议通过了《关于公 司<2023年度利润分配预案>的议案》，鉴于公司2023年度尚未盈利，为了更好的 维护全体股东的长远利益，从公司实际情况出发，董事会同意公司2023年度不进 行利润分配。本方案符合公司章程规定的利润分配政策和公司已披露的股东回报 规划。 （二）监事会意见 由于公司 2023 年 12 月 31 日母公司财务报表未分配利润为负数，尚不满足 利润分配条件，同意本 ...

Financial Performance - The company reported a revenue of CNY 210.04 million for 2023, representing a 34.48% increase compared to CNY 156.19 million in 2022[20]. - The net loss attributable to shareholders was CNY 156.39 million for 2023, with a net loss of CNY 214.01 million after excluding non-recurring items[4]. - The company's operating revenue for 2023 reached ¥198,641,728.91, an increase of 34.48% compared to the previous year, driven by growth in orthopedic surgical robots and related products[21]. - The net profit attributable to shareholders was a loss of ¥156,386,688.67, which represents an increase in loss of 41.42% year-over-year[23]. - Basic earnings per share for 2023 were -¥0.35, a decline of 34.62% compared to the previous year[22]. - The company's total assets increased by 15.10% year-over-year, reaching ¥1,619,474,854.92 at the end of 2023[21]. - The weighted average return on equity was -12.36%, a decrease of 1.59 percentage points compared to the previous year[22]. - The company reported a significant increase in sales expenses by 50.83% to CNY 137.86 million[91]. - The company reported a total revenue of 7,651.40 million in the latest financial period, with a slight increase of 0.16% compared to the previous period[144]. Research and Development - Research and development expenses accounted for 71.63% of operating revenue, a decrease of 6.89 percentage points from the previous year[22]. - The company has established a comprehensive R&D system covering cutting-edge technology research, advanced product pre-research, and product development[43]. - The company has developed high-precision online calibration technology for surgical robots, achieving an error margin of less than 0.5 mm[52]. - The company has created algorithms for multi-modal medical image fusion, allowing for high-precision integration of preoperative and intraoperative images[53]. - The company submitted 87 new patent applications during the reporting period, including 35 invention patents, and obtained 59 new patent authorizations, with 9 being invention patents[66]. - The company has established a collaborative innovation mechanism with renowned universities and hospitals, enhancing its R&D capabilities in the field of medical robotics[77]. - The company has completed the iteration of three generations of orthopedic surgical robot products, enhancing its competitive edge in the market[76]. - The company is currently developing the international version of its orthopedic surgical robot, aiming for CE certification[73]. Market Expansion and Strategy - The company aims to expand its market share and accelerate the implementation of application scenarios, focusing on technological innovation and building an ecosystem centered around orthopedic surgical robots[4]. - The company is preparing to expand into international markets and has made progress in discussions with potential international partners[37]. - The company plans to continue investing in market expansion and new product development to drive future growth[23]. - The company is focusing on market expansion and new product development, aiming to enhance its competitive edge in the medical technology sector[144]. - Market expansion plans include entering three new international markets by the end of 2024[146]. - The company is exploring potential mergers and acquisitions to enhance its technological capabilities and market presence[149]. Operational Efficiency and Governance - The company has received a standard unqualified audit report from its accounting firm for the reporting period[7]. - The company maintained a strict governance structure in compliance with relevant laws and regulations, ensuring the protection of shareholder interests[138]. - The company has not reported any significant changes in the independence of its operations from the controlling shareholder[138]. - The company has established effective internal control mechanisms to enhance operational efficiency and risk management[185]. - The company emphasizes the protection of shareholder rights, particularly for minority shareholders, ensuring fair and transparent information disclosure[198]. Employee and Talent Management - The company has a total of 328 valid patents, including 51 invention patents, and has also registered 36 software copyrights[66]. - The company emphasizes talent development, conducting various training programs to enhance employee skills and overall capabilities[171]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 1,440.83 million RMB[153]. - The company implemented a restricted stock incentive plan, granting 859.75 thousand shares to 197 individuals, which represents 55.64% of the total employee count[177]. - The company has established employee stock ownership plans through platforms holding a total of 42,245,560 shares[181]. Environmental and Social Responsibility - The company invested 14.25 million yuan in environmental protection during the reporting period[188]. - The company actively promotes ESG management and adheres to environmental protection responsibilities[187]. - The company donated a total of 35 million yuan to charitable causes, including 30 million yuan to the China Aging Development Foundation[197]. - The company is not involved in high pollution or high energy consumption industries, ensuring compliance with environmental standards[190].

上会会计师事务所（特殊普通合伙） 中国 上海 六十师事务所(特殊着通合伙) i Ecoliliod Public Accountants (Special Geneval Partnership) 关于北京天智航医疗科技股份有限公司 2023 年度营业收入扣除事项的专项核查报告 上会师报字(2024)第 4622 号 关于北京天智航医疗科技股份有限公司 2023 年度营业收入扣除事项的专项核查报告 上会师报字(2024)第 4622 号 北京天智航医疗科技股份有限公司全体股东: 我们接受委托,对北京天智航医疗科技股份有限公司(以下简称"北京天智 航")2023 年度财务报表进行审计，并出具了上会师报字(2024)第 4616 号审计报告。 在此基础上,我们检查了后附的北京天智航管理层编制的《2023 年度营业收入扣除 情况表》(以下简称"营业收入扣除情况表")。 一、管理层的责任 北京天智航管理层的责任是提供真实、合法、完整的相关资料,按照《上海证 券交易所股票上市规则》(上证发〔2023〕127 号)及《上海证券交易所科创板股票上 市规则》(上证发(2023) 128 号)及《科创板上市公司自律监管指南第 ...

一、会计师事务所基本情况 1、基本信息及资质条件 （1）事务所名称：上会会计师事务所（特殊普通合伙） 北京天智航医疗科技股份有限公司 2023 年度会计师事务所履职情况评估报告 北京天智航医疗科技股份有限公司（以下简称"天智航"或"公司"）聘请 上会会计师事务所（特殊普通合伙）（以下简称"上会"）作为公司2023年度财 务报告出具审计报告的会计师事务所。 根据《国有企业、上市公司选聘会计师事务所管理办法》《上海证券交易所 科创板上市公司自律监管指引第1号——规范运作》要求，公司对上会在2023年 度的审计工作的履职情况进行了评估。具体情况如下： 上会所近三年因执业行为受到监督管理措施4次，未受到刑事处罚、行政处 罚、自律监管措施和纪律处分。6名从业人员近三年因执业行为受到监督管理措 施3次，未受到刑事处罚、行政处罚和自律监管措施。 二、会计师事务所履职情况评估 （5）首席合伙人：张晓荣 （6）业务资质：会计师事务所证券、期货相关业务许可证（证书号32）； 会计师事务所执业证书（编号31000008）；首批获准从事金融相关审计业务会计 师事务所资质，批准文号：银发（2000）358号；中国银行间市场交易商协会会 ...

本人作为北京天智航医疗科技股份有限公司（以下简称"公司"）的独立董事， 在 2023 年度，按照《公司法》《证券法》《上市公司治理准则》等法律法规、规 范性文件，以及《公司章程》和《独立董事工作制度》等相关规定，忠实履行职 责，在董事会日常工作及重要决策中尽职尽责，并对董事会的相关事项发表了独 立意见，从公司整体利益出发，发挥了独立董事的应有作用，维护了公司和全体 股东特别是中小股东的合法权益。现将 2023 年度本人履行独立董事职责的工作 情况汇报如下： 一、独立董事的基本情况 （一）个人工作履历、专业背景及兼职情况 本人张瑞君，1961 年出生，中国国籍，无境外永久居留权。毕业于中国人民 大学，博士研究生学历。1992 年 12 月就职于中国人民大学，主要从事会计、财 务管理与信息技术相结合的交叉学科的研究和教学工作。中国人民大学商学院教 授、博士生导师、财政部会计信息化委员会咨询专家、中国会计学会会计信息化 专业委员会委员，中国注册会计师。2023 年 9 月起，任公司独立董事。 （二）是否存在独立性情况说明 作为公司的独立董事，除在公司担任独立董事以外，本人及直系亲属均未在 公司或其附属企业任职，也未 ...

证券代码：688277 证券简称：天智航 公告编号：2024-018 北京天智航医疗科技股份有限公司 2023 年度募集资金存放与使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 按照中国证监会发布的《上市公司监管指引第 2 号——上市公司募集资金管 理和使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号）和《上海 证券交易所科创板上市公司自律监管指引第 1 号——规范运作（2023 年 12 月修 订）》（上证发〔2023〕194 号）及北京天智航医疗科技股份有限公司（以下简 称"公司"）募集资金使用管理办法等规定，公司董事会编制了公司 2023 年年 度募集资金存放与使用情况的专项报告，具体如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 1、首次公开发行股票 根据中国证券监督管理委员会于 2020 年 5 月 26 日出具的《关于同意北京天 智航医疗科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2020〕 1001 号），公司首次向社会公众公开发行人民币 ...